1. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T 1984 Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-823
2. Yu CM, Sanderson JE 1999 Plasma brain natriuretic peptide--an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail 1:59-65
3. Cruden NLM, Witherow FN, Webb DJ, Fox KAA, Newby DE 2004 Bradykinin Contributes to the Systemic Hemodynamic Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure. Arterioscler Thromb Vasc Biol 24:1043-1048
4. Erdmann E, Lechat P, Verkenne P, Wiemann H 2001 Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 3:469-479
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial 1999 Lancet 353:9-13
6. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717
7. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators 2003 Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 348:1309-1321
8. The Heart Outcomes Prevention Evaluation Study Investigators 2000 Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. N Engl J Med 342:145-153
9. Pliquett R, Fasshauer M, Bluher M, Paschke R 2004 Neurohumoral stimulation in type-2-diabetes as an emerging disease concept. Cardiovasc Diabetol 3:4
10. Expert Panel on Detection EaToHBCiA 2001 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497
11. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J 2003 Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study. Circulation 108:414-419
12. Lindholm LH, Ibsen H, Borch J, Olsen MH, Wachtell K, Dahlof B, Devereux RB, Beevers G, de F, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe P, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S, 2002 Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 20:1879-1886
13. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials 2004 Am Heart J 148:52-61
14. Stalcup SA, Davidson D, Mellins RB 1982 Endothelial cell functions in the hemodynamic responses to stress. Ann N Y Acad Sci 401:117-131
15. Vischer UM, Wollheim CB 1997 Epinephrine induces von Willebrand factor release from cultured endothelial cells: involvement of cyclic AMP-dependent signalling in exocytosis. Thromb Haemost 77:1182-1188
16. Drummond GR, Cai H, Davis ME, Ramasamy S, Harrison DG 2000 Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ Res 86:347-354
17. Schade R, Gohler K, Burger W, Hirschelmann R 1987 Modulation of rat C-reactive protein serum level by dexamethasone and adrenaline--comparison with the response of alpha 2-acute phase globulin. Agents Actions 22:280-287
18. Bachman ES, Dhillon H, Zhang CY, Cinti S, Bianco AC, Kobilka BK, Lowell BB 2002 betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 297:843-845
19. Aizawa T, Ishizaka N, Usui S, Ohashi N, Ohno M, Nagai R 2002 Angiotensin II and catecholamines increase plasma levels of 8-epi-prostaglandin F(2alpha) with different pressor dependencies in rats. Hypertension 39:149-154
20. De L, Terreni L, Sironi M, De S 1998 The sympathetic nervous system tonically inhibits peripheral interleukin-1beta and interleukin-6 induction by central lipopolysaccharide. Neuroscience 83:1245-1250
21. Luchner A, Stevens TL, Borgeson DD, Redfield M, Wei CM, Porter JG, Burnett JC 1998 Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 274:H1684-H1689
22. Kikuta K, Yasue H, Yoshimura M, Morita E, Sumida H, Kato H, Kugiyama K, Ogawa H, Okumura K, Ogawa Y, Nakao K 1996 Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J 132:101-107
23. Morita H, Nishida Y, Motochigawa H, Kangawa K, Minamino N, Matsuo H, Hosomi H 1989 Effects of brain natriuretic peptide on renal nerve activity in conscious rabbits. Am J Physiol 256:R792-R796
24. Kambayashi Y, Nakao K, Kimura H, Kawabata T, Nakamura M, Inouye K, Yoshida N, Imura H 1990 Biological characterization of human brain natriuretic peptide (BNP) and rat BNP: species-specific actions of BNP. Biochem Biophys Res Commun 173:599-605
25. Lee SC, Stevens TL, Sandberg SM, Heublein DM, Nelson SM, Jougasaki M, Redfield MM, Burnett JC 2002 The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 8:149-154
26. Catuzzo B 2003 In patients with severe systolic dysfunction, only brain natriuretic peptide is related to diastolic restrictive pattern.
27. Roks AJ, van G, Pinto YM, Buikema H, Henning RH, de Z, van G 1999 Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 34:296-301
28. Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM 1992 In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 19:692-696
29. Barton M, Shaw S, Uscio LV, Moreau P, Luscher TF 1997 Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 238:861-865
30. Browatzki M, Schmidt J, Kubler W, Kranzhofer R 2000 Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Basic Res Cardiol 95:98-105
31. Stankova J, Orleans J, Rola P 1996 ET-1 induces IL-6 gene expression in human umbilical vein endothelial cells: synergistic effect of IL-1. Am J Physiol 271:C1073-C1078
32. Zucker IH, Wang W, Pliquett RU, Liu JL, Patel KP 2001 The regulation of sympathetic outflow in heart failure. The roles of angiotensin II, nitric oxide, and exercise training. Ann N Y Acad Sci 940:431-443
33. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K, Harada E, Nakayama M, Nakamura S, Ito T, Shimasaki Y, Saito Y, Nakao K 2001 Aldosterone production is activated in failing ventricle in humans. Circulation 103:72-77
34. Weber KT 2001 Aldosterone in congestive heart failure. N Engl J Med 345:1689-1697
35. Losel RM, Feuring M, Falkenstein E, Wehling M 2002 Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids 67:493-498
36. Rocha R, Williams GH 2002 Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 62:723-731
37. Funder J 2001 Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol 28:1002-1006
38. Neumann S, Huse K, Semrau R, Diegeler A, Gebhardt R, Buniatian GH, Scholz GH 2002 Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 39:756-760
39. Liu JL, Pliquett RU, Brewer E, Cornish KG, Shen YT, Zucker IH 2001 Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure. Am J Physiol Regul Integr Comp Physiol 280:R1906-R1913
40. Rossi GP, Cavallin M, Nussdorfer GG, Pessina AC 2001 The endothelin-aldosterone axis and cardiovascular diseases. J Cardiovasc Pharmacol 38 Suppl 2:S49-S52
41. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial 1996 JAMA 275:370-375
42. Hunt BE, Davy KP, Jones PP, DeSouza CA, Van P, Tanaka H, Seals DR 1997 Systemic hemodynamic determinants of blood pressure in women: age, physical activity, and hormone replacement. Am J Physiol 273:H777-H785
43. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N, 2002 Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49-57
44. Writing Group for the Women's Health Initiative Investigators 2002 Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA 288:321-333
45. Kuller LH 2003 Hormone Replacement Therapy and Risk of Cardiovascular Disease: Implications of the Results of the Women's Health Initiative. Arterioscler Thromb Vasc Biol 23:11-16
46. Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, Coats AJ, Anker SD, Gatzoulis MA 2002 Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 106:92-99
47. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Zucker IH 2004 Superoxide Mediates Sympathoexcitation in Heart Failure: Roles of Angiotensin II and NAD(P)H Oxidase. Circ Res 95:937-944
48. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GDO, Pepys MB, Gudnason V 2004 C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease. N Engl J Med 350:1387-1397
49. Ridker PM, Cook N 2004 Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores. Circulation 109:1955-1959
50. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T 2001 Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104:2673-2678
51. Koukkunen H, Penttila K, Kemppainen A, Halinen M, Penttila I, Rantanen T, Pyorala K 2001 C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med 33:37-47
52. Sabatine MS, Morrow DA, de L, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E 2002 Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105:1760-1763
53. Zhang H, Schmeisser A, Garlichs CD, Plotze K, Damme U, Mugge A, Daniel WG 1999 Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 44:215-222
54. Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz V, Ocampo ON, Eng C 1999 Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99:2645-2651
55. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G 2001 Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104:982-985
56. Orth D.N., Kovacs W.J. 1998 The adrenal cortex. In “Williams Textbook of Endocrinology”. 9th edition; WB Saunders, Philadelphia
57. Heart Protection Study Collaborative Group2002 MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 6;360(9326):23-33
58. Gomez-Sanchez CE, Gomez-Sanchez EP 2001 Editorial: Cardiac steroidogenesis-new sites of synthesis, or much ado about nothing ? J Clin Endocrinol Metab 86(11): 5121- 5126